Argenx’s cusatuzumab in previously untreated AML draws varied expert forecasts for safety potential in Phase Ib
No new safety concerns coming out of Phase Ib trial desired to move forward Moving to Phase II, triplet needs…
Latest Oncology
-
21 hours
-
2 days
-
Arcus’ Phase Ib/II etrumadenant has intriguing mechanism for 1L pancreatic cancer but kinks need to…3 days
-
3 days
-
21 hours
-
2 days
-
Arcus’ Phase Ib/II etrumadenant has intriguing mechanism for 1L pancreatic cancer but kinks need to…3 days
-
3 days